Background: Although y6 T cells are a major compo-
INTRODUCTION
Inflammatory bowel disease (IBD) represents a complex group of idiopathic chronic inflammatory disorders of which Crohn's disease (CD) and ulcerative colitis (UC) are the major forms. While there are several features that distinguish CD and UC, there are many epidemiological, clinical, radiologic, endoscopic, and histologic features that are shared between these two disorders.
Several immunologic and histopathologic features of UC and CD can be explained as a defect in mucosal immunoregulation, and as a direct or indirect consequence of persistent mucosal T cell activation (1) (2) (3) (4) . Experimental evidence for a direct role for T cells in IBD comes from various animal models, especially "gene knock-out" strains that spontaneously develop bowel lesions. In particular, the presence of intestinal inflammation in transgenic mice deficient in aC3 T cells (5) or T cell-derived cytokines 184 Molecular Medicine, Volume 3, Number 3, March 1997 such as interleukin 2 (IL-2) (6) suggest that T cells are responsible for the homeostatic regulation of mucosal immune responses.
In the human intestine, y&' cells are a major component (30-40%) of the T cells in the intraepithelial spaces and the majority (>70%) express V6I-encoded receptors (7) . In view of the predominance of V61+ cells within the human intestinal mucosa and the possibility that they have similar effector functions to their murine counterparts, it seems likely that they may play an important role in the generation and/or regulation of inflammatory responses in the intestinal mucosa. The ability of yS T cells to interact with and influence the activity of a variety of stromal cells (8) (9) (10) , including epithelial cells (8,1 1) , and the finding that the severity of IBD in T cell receptor (TCR)-a/3 deficient mice is significantly reduced when crossed with mice lacking ,y6 T cells (5) are all consistent with an immunoregulatory role for mucosal 'y6 T cells.
Whereas several groups of investigators have described an increase in the number of V81 + intraepithelial (IE) y8 T cells within the intestine of patients with coeliac disease (12) (13) (14) (15) (16) , the immunohistochemical analyses of mucosal yB T cells in patients with IBD have generated contradictory results (16, 17) . Although one group has shown that the distribution and relative number of TCR-5+ cells in sections of colonic mucosa obtained from IBD patients was similar to that in sections of normal colonic mucosa (16) , the results of another study showed that there were fewer TCR-6+ cells in the inflamed mucosa of patients with IBD, and particularly, those with UC (17) . Thus, evidence for the involvement of y8 T cells in IBD remains inconclusive. To investigate further the possible involvement of mucosal y6 T In Situ Hybridization In situ hybridization was used to identify and localize populations of y8 T cells and IFN-,y-producing cells within frozen sections of intestine as described previously (22, 26, 27 Further characterization of the mucosal y6 T cells in the normal and inflamed colon using TCR-V,y/8-(J6)-specific antibodies revealed some interesting differences in the y6 T cell subsets present (Fig. iB) . In the noninvolved colonic mucosa, V81 + yS T cells comprised a major subset (43-52%) of IE 'y8 T cells. Of these cells, V61-J8I-encoded TCR-8 chains predominated (63-76% of V81+ cells). By contrast, in the LP, V51+ y8 T cells represented a minor subset (6-10%) of y8 T cells; as seen among IEL, VI+-J6I was the predominant (43-58%) TCR-6 chain expressed by these cells. Thus, VSI-JSI-encoded receptors predominate among V61 + yS T cells in both the IE space and LP of the normal colonic mucosa. Vy9/VS2+ y6 T cells that make up the largest -y5 T cell subset in the blood (Fig. IB) had a distribution in the normal colonic mucosa that was reciprocal to that of the V61 subset. Whereas they represented a minor subset (13%) of TCRy75+ IEL, they were the major y6 T cell subset in the LP (67-79% of TCR--y6+ cells).
In comparing the y6T cell subset distribution in the involved and noninvolved mucosa, the most striking difference was the increase in the proportion of VS1 RT-PCR was carried out as described in Fig. 2 Table 1) were also used as noninvolved, "normal" controls. The results of this analysis shown in Fig. 2 identify changes in the pattern of VS1 -J6 expression in the involved mucosa compared to the noni-nvolved mucosa and blood of IBD patients. The V8-J5 profile of the noninvolved colonic mucosa (* profiles in Fig. 2 (Fig. 1) , and it also demonstrates the utility of this procedure for TCR--ya repertoire analysis. DNA sequence analysis of randomly selected V1-Ca cDNAs from involved and noninvolved mucosal mRNA samples from a patient with UC did not identify any V51 receptors that were unique to the inflamed colonic mucosa (data not shown). All These T cell populations were isolated from the mononuclear cell fraction of noninvolved and involved mucosa from three patients with CD using immunomagnetic selection. The isolated populations were routinely >95% CD3+ and the degree of contamination of the y8 fraction by aI3+ cells and the af3 fraction by y6+ cells was routinely <10% (data not shown). As seen in our previous flow cytometric analyses of mucosal T cells (Fig. IA) , VS1 + cells were the major y6 T cell subset (67 ± 8%) in the involved mucosa compared with the noninvolved mucosa (12 ± 2%). The increase in the number of T cells in the LP of involved mucosa (see above) was paralleled by an increase in the frequency of cells that constitutively expressed IFN-,y-mRNA (Table 3) . (39, 40) . Extensive epithelial cell damage could, however, enable IEL such as VMI + cells to "leak" into the LP, thus contributing to the increase in the number of V81+ cells seen in the LP of IBD patients. The third possibility is that the activation of V61 -expressing yS T cells is antigen-independent and does not involve the TCR/CD3 complex. The existence of alternative, antigenindependent pathways of mucosal T cell activation is suggested by the finding that LP T cells, unlike peripheral blood T cells, from normal and IBD patients exhibit vigorous proliferative responses via the CD2/CD28 signaling pathway (41) (42) (43) (44) (45) . The presence in the inflamed mucosa of large numbers of activated T cells that produce cytokines (46) (47) (48) (49) could also serve to activate, in a "bystander" manner, V61 + cells (50) , as well as to maintain a population of chronically activated T cells within the mucosa.
The y8 T cells that accumulate in the inflamed mucosa of patients with CD possess two functional characteristics that are relevant to the pathophysiology of this IBD. The first is that they are a major source of the proinflammatory cytokine IFN-y, which has long been shown to mediate epithelial cell injury (51) . Although the constitutive production of IFN-'y by colonic lymphocytes from IBD patients has been previously reported (44, 49, 51) (52, 53) , the processes regulating normal fibroblast activity are poorly understood. One way in which the activity of fibroblasts and other stromal cells could be regulated and coordinated is through direct interactions with other cells, such as VS1 + y6 T cells. The production by -yB T cells of tumor necrosis factor a (TNF-a), ILI -f, and transforming growth factor ,B (TGF-,B) (54) that can promote fibroblast growth and collagen synthesis (55) , and the observation that epithelial-associated y8 T cells in the skin can influence the activity of keratinocytes by the production of keratinocyte cell growth factor (8) are all consistent with this hypothesis. This immunoregulatory property of yS T cells is further substantiated by the results from a variety of animal models of infectious disease in which the ability of -yS T cells to influence the activity of other cell populations and the outcome of inflammatory immune responses has been demonstrated (56 -6 1). Since it has previously been shown that fibroblasts can prolong the survival of T cells in culture after the removal of IL-2 and antigen (62) , fibroblast adherence may also provide a means of localizing or retaining activated, peripheral blood-derived, V51 + cells in the inflamed colon. Although we do not yet have an explanation for the differences in 'y$ T cell subsets adhering to colonic fibroblasts, it could be related to quantitative and/or qualitative changes in the expression of adhesion/integrin molecules such as LFA-1 and VLA-5 by V81+ cells (9, 33, 63) and their reciprocal receptors, ICAM-1 and fibronectin, respectively, by fibroblasts (9, 33) . The preferential association of VS1 + y8 T cells with fibroblasts provides a possible explanation for their accumulation in the lungs (64) and joints (65) (66) (67) (68) (69) in sarcoidosis and rheumatoid arthritis patients, respectively. Interestingly, inflammatory disorders of the lung, joints, skin, and eye are often present as extraintestinal manifestations of IBD (70) , raising the possibility that VS1 + cells activated in the gut could migrate to other extraintestinal sites 199 where, as a result of their ability to interact with fibroblasts or other connective tissue elements, they accumulate and can contribute to the inflammatory immune reaction and inflammation at these sites.
In summary, we have demonstrated that the chronic inflammatory reaction and tissue injury that occurs in the colon of patients with IBD is associated with distinct changes in the number, distribution, composition, and effector function of mucosal 'y T cells, particularly V81 -expressing cells. These findings suggest that these cells contribute to at least some of the immunological and pathological changes present in the inflamed mucosa of patients with IBD, and particularly CD.
